The Industry Lawsuit: NJOY and the PMTA Logjam

The NJOY/Altria lawsuit is more than just one company's complaint — it's a window into broader industry frustration with the pace of PMTA reviews.

Here's what you need to know:

The suit targets the 2021 rule that established PMTA scientific evidence standards
Plaintiffs argue that FDA's slow processing has created an "insurmountable logjam"
The WSJ reports that review times often take years, far exceeding Congress's six-month mandate
The suit comes as the administration is already planning to revisit the 2021 rule — which could make some of the legal arguments moot, or could align with what the court ultimately orders

For context on what PMTA actually is and why it matters, check out our PMTA glossary breakdown of the process and its history.

The NJOY/Altria lawsuit is more than just one company's complaint — it's a window into broader industry frustration with the pace of PMTA reviews.

Here's what you need to know:

The suit targets the 2021 rule that established PMTA scientific evidence standards
Plaintiffs argue that FDA's slow processing has created an "insurmountable logjam"
The WSJ reports that review times often take years, far exceeding Congress's six-month mandate
The suit comes as the administration is already planning to revisit the 2021 rule — which could make some of the legal arguments moot, or could align with what the court ultimately orders

For context on what PMTA actually is and why it matters, check out our PMTA glossary breakdown of the process and its history.

Create content.
Unlock new opportunities.